anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants in the NI group received an iNIP according to energy and protein intake requirements in addition to dietary advice based on face-to-face interviews with their family members during hospitalization. After discharge, phone calls are adopted for prescribing iNIPs. Anthropometry (i.e., body mass index, limb circumference, and subcutaneous fat thickness), blood parameters (i.e., albumin and total lymphocyte count), hospital stay, Mini-Nutritional Assessment-Short Form (MNA-SF) score, target daily calorie intake, total calorie intake adherence rate, and three-major-nutrient intake were assessed during hospitalization and 3 and 6 months after discharge. Both groups received regular follow-up through phone calls. Furthermore, the rate of readmission resulting from pneumonia was recorded after discharge.
Male or female subject between the ages of 2-12, previously admitted to the Medical University of South Carolina for inpatient vEEG monitoring in the MUSC Epilepsy Monitoring Unit with at least one PNES was recorded during that admission. Validation of Brain Sentinel's sEMG Post-processing algorithm will involve prospective evaluation of at least 30 PNES events in this group.
Hearing loss is a major health concern affecting millions of people worldwide with currently limited treatment options. In clarin-2-deficient Clrn2-/- mice, used here as a model of progressive hearing loss, we report synaptic auditory abnormalities in addition to the previously demonstrated defects of hair bundle structure and mechanoelectrical transduction. We sought an in-depth evaluation of viral-mediated gene delivery as a therapy for these hearing-impaired mice. Supplementation with either the murine Clrn2 or human CLRN2 genes preserved normal hearing in treated Clrn2-/- mice. Conversely, mutated forms of CLRN2, identified in patients with post-lingual moderate to severe hearing loss, failed to prevent hearing loss. The ectopic expression of clarin-2 successfully prevented the loss of stereocilia, maintained normal mechanoelectrical transduction, preserved inner hair cell synaptic function, and ensured near-normal hearing thresholds over time. Maximal hearing preservation was observed when Clrn2 was delivered prior to the loss of transducing stereocilia. Our findings demonstrate that gene therapy is effective for the treatment of post-lingual hearing impairment and age-related deafness associated with CLRN2 patient mutations.
BACKGROUND: Homologous recombination deficiency (HRD), though largely uncharacterized in clear cell renal cell carcinoma (ccRCC), was found associated with RAD51 loss of expression. PBRM1 is the second most common mutated genes in ccRCC. Here, we introduce a HRD function-based PBRM1-RAD51 ccRCC classification endowed with diverse immune checkpoint blockade (ICB) responses.
METHODS: Totally 1542 patients from four independent cohorts were enrolled, including our localized Zhongshan hospital (ZSHS) cohort and Zhongshan hospital metastatic RCC (ZSHS-mRCC) cohort, The Cancer Genome Atlas (TCGA) cohort and CheckMate cohort. The genomic profile and immune microenvironment were depicted by genomic, transcriptome data and immunohistochemistry.
RESULTS: We observed that PBRM1-loss ccRCC harbored enriched HRD-associated mutational signature 3 and loss of RAD51. Dual-loss of PBRM1 and RAD51 identified patients hyper-sensitive to immunotherapy. This dual-loss subtype was featured by M1 macrophage infiltration. Dual-loss was, albeit homologous recombination defective, with high chromosomal stability.
CONCLUSIONS: PBRM1 and RAD51 dual-loss ccRCC indicates superior responses to immunotherapy. Dual-loss ccRCC harbors an immune-desert microenvironment but enriched with M1 macrophages. Dual-loss ccRCC is susceptible to defective homologous recombination but possesses high chromosomal stability.
Methods, systems, and computer storage media are provided for generating simulation graphs using real-time clinical data. A user may indicate one or more scenario variables to apply to an area of interest. A simulation graph is then generated that includes at least an indication of a scenario status. The scenario status indicates an expected result based on the one or more scenario variables selected by the user. The simulation graph may also include a baseline status indicating an expected result should no changes be made to a current environment. Multiple simulation graphs for varying areas of interest may be generated and compared to one another such that a user is able to quickly identify efficient solutions.
BACKGROUND AND OBJECTIVES: Dynamic handwriting analysis, due to its noninvasive and readily accessible nature, has emerged as a vital adjunctive method for the early diagnosis of Parkinson's disease (PD). An essential step involves analysing subtle variations in signals to quantify PD dysgraphia. Although previous studies have explored extracting features from the overall signal, they may ignore the potential importance of local signal segments. In this study, we propose a lightweight network architecture to analyse dynamic handwriting signal segments of patients and present visual diagnostic results, providing an efficient diagnostic method.
METHODS: To analyse subtle variations in handwriting, we investigate time-dependent patterns in local representation of handwriting signals. Specifically, we segment the handwriting signal into fixed-length sequential segments and design a compact one-dimensional (1D) hybrid network to extract discriminative temporal features for classifying each local segment. Finally, the category of the handwriting signal is fully diagnosed through a majority voting scheme.
RESULTS: The proposed method achieves impressive diagnostic performance on the new DraWritePD dataset (with an accuracy of 96.2%, sensitivity of 94.5% and specificity of 97.3%) and the well-established PaHaW dataset (with an accuracy of 90.7%, sensitivity of 94.3% and specificity of 87.5%). Moreover, the network architecture stands out for its excellent lightweight design, occupying a mere 0.084M parameters, with only 0.59M floating-point operations. It also exhibits nearly real-time CPU inference performance, with the inference time for a single handwriting signal ranging from 0.106 to 0.220 s.
CONCLUSIONS: We present a series of experiments with extensive analysis, which systematically demonstrate the effectiveness and efficiency of the proposed method in quantifying dysgraphia for a precise diagnosis of PD.
The invention provides a health-are product promoting and improving microcirculation and a preparation method thereof. The health-care product consists of an extract from pueraria, a salvia extract, a gynostemma pentaphylla extract, a medlar extract, a rheum officinale extract, a grape seed extract, a Chinese yam extract, a hawthorn extract and a semen cassiae extract. The method comprises the following steps: preparing; mixing; filling; bottling; storing. The health-are product prompting and improving microcirculation provided by the invention can be used for expanding blood vessels, increasing the blood flow volume, improve the blood flow velocity, and promote blood circulation to remove blood stasis, so that microcirculation of human body can be promoted and improved. In addition, the technical scheme provided by the invention further has the gastrointestinal protective function, protecting gallbladder and liver, protecting renal function and accelerating perspiring function of the sweat gland. As the health-care product provided by the invention is not a medicine, so that a user taking the product provided by the invention is free from dependency, and no side effects of the product taken are generated.
Compositions contain 0.01-20% drug and 80-99.99% of a hydrocarbonaceous carrier which is a semisolid at room temperature and melts at 30-100 deg.C. Typical carriers are petrolatum or lanolin. An emulsifier is optionally present. Suitable drugs for inclusion in the compositions are listed. Delivery to the eye is particularly in nebulized form. Compositions containing Vitamin A and Vitamin B12 as active ingredients are exemplified.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention describes novel derivatives of neuraminic acid of the general formula (I)   where R 1  means methyl group; R 2 , R 3  and R 4  can be similar or distinct and each means hydrogen atom or aliphatic acyl group containing 3-25 carbon atoms; W means hydrogen atom or ester residue under condition that compounds of the formula (I) where each of R 2 , R 3  and R 4  and W means hydrogen atom are excluded. Derivatives of neuraminic acid of the present invention show high inhibitory effect with respect to sialidase in vivo and they are useful as therapeutic agents or agents for prophylaxis of viral influenza infection. Invention describes also pharmaceutical composition and method of treatment and prophylaxis of influenza. EFFECT: new compounds indicated above, valuable medicinal properties. 33 cl, 4 tbl, 11 ex
PROBLEM TO BE SOLVED: To obtain an agent for lowering a blood sugar level and a food for lowering a blood sugar level, capable of stably exhibiting an excellently lowering action on blood sugar level, effectively useful for treating and preventing diabetes and obesity, aiming slimming such as diet, stabilizing a physical condition in overeating, etc. SOLUTION: This agent for lowering a blood sugar level contains at least one of Sinocrassula indica (Decne.) Berger, Sinocrassula indica (Decne.) Berger var. obtuslfolla (Frod.) S. H. Fu., and their extracts. This food for lowering a blood sugar level contains the agent for lowering a blood sugar level.
The present invention relates to a method for producing soybean paste using a Foeniculum vulgare Miller seed extract as an active ingredient. More specifically, the present invention relates to a method for producing soybean paste, and to a use of a soybean paste composition produced through the same. The method comprises: a fermented soybean malt producing step of soaking soybeans in water, and fermenting the same by Bacillus subtilis; a fermented soybean malt pulverizing step of pulverizing fermented soybean malt of the fermented soybean malt producing step into powder; a soybean paste producing step of mixing a Foeniculum vulgare Miller seed extract, starch, salt, and water with the fermented soybean malt powder produced through the fermented soybean malt pulverizing step; and an aging step of aging soybean paste produced through the soybean paste producing step at a low temperature. According to the present invention, an effect of soybean paste and active ingredients of a Foeniculum vulgare Miller seed extract are combined to show a synergy effect. Through the aging step, palatability such as a taste, a color, a fragrance, and a texture are improved, and an antioxidant activity, a bone cell differentiation inhibiting function, and a thromboclastic function can be more improved. Thus, new health functional food can be produced by using the soybean paste or an extract thereof produced according to the method of the present invention.
FIELD: medicine, otorhinolaryngology. SUBSTANCE: invention proposes the composition containing ciprofloxacine and method of its preparing. Composition has from 0.12 to 0.6 g/ml of ciprofloxacine chlorohydrate monohydrate (this value is equivalent to 0.1-0.5% of free base); 0.05-0.3 g/ml of nonionic surface-active substance; from 0.5 to 2.0 g/ml of thickening agent and water up to 100 ml. Method of preparing involves the dispersion of thickening agent at heating, addition of surface-active substance, acetic acid, sodium acetate solution and ciprofloxacine and pH value is brought about to 4.5-4.9. Composition has no preserving agents and exhibits stability. EFFECT: improved method of preparing. 11 cl, 1 tbl, 6 ex
Antibiotic related intestinal injury in early life affects subsequent health and susceptibility. Here, we employed weaned piglets as a model to investigate the protective effects of baicalin against early-life antibiotic exposure-induced microbial dysbiosis. Piglets exposed to lincomycin showed a marked reduction in body weight (p < 0.05) and deterioration of jejunum intestinal morphology, alongside an increase in antibiotic-resistant bacteria such as Staphylococcus, Dolosicoccus, Escherichia-Shigella, and Raoultella. In contrast, baicalin treatment resulted in body weights, intestinal morphology, and microbial profiles that closely resembled those of the control group (p > 0.05), with a significant increase in norank_f_Muribaculaceae and Prevotellaceae_NK3B31_group colonization compared with lincomycin group (p < 0.05). Further analysis through fecal microbial transplantation into mice revealed that lincomycin exposure led to significant alterations in intestinal morphology and microbial composition, notably increasing harmful microbes and decreasing beneficial ones such as norank_Muribaculaceae and Akkermansia (p < 0.05). This shift was associated with an increase in harmful metabolites and disruption of the calcium signaling pathway gene expression. Conversely, baicalin supplementation not only counteracted these effects but also enhanced beneficial metabolites and regulated genes within the MAPK signaling pathway (MAP3K11, MAP4K2, MAPK7, MAPK13) and calcium channel proteins (ORA13, CACNA1S, CACNA1F and CACNG8), suggesting a mechanism through which baicalin mitigates antibiotic-induced intestinal and microbial disturbances. These findings highlight baicalin's potential as a plant extract-based intervention for preventing antibiotic-related intestinal injury and offer new targets for therapeutic strategies.
Drugs that act directly on the renin-angiotensin system can cause fetal and neonatal morbidity and death when administered to pregnant women. Several dozen cases have been reported in the world literature of patients who were taking angiotensin converting enzyme inhibitors. When pregnancy is detected, discontinue Benicar as soon as possible.

The use of drugs that act directly on the renin-angiotensin system during the second and third trimesters of pregnancy has been associated with fetal and neonatal injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure and death. Oligohydramnios has also been reported, presumably resulting from decreased fetal function; oligohydramnios in this setting has been associated with fetal limb contractures, craniofacial deformation and hypoplastic lung development. Prematurity, intrauterine growth retardation and patent ductus arteriosus have also been reported, although it is not clear whether these occurrences were due to exposure to the drug.

These adverse effects do not appear to have resulted from intrauterine drug exposure that has been limited to the first trimester. Mothers whose embryos and fetuses are exposed to an angiotensin II receptor antagonist only during the first trimester should be so informed. Nonetheless, when patients become pregnant, physicians should have the patient discontinue the use of Benicar as soon as possible.

Rarely (probably less often than once in every thousand pregnancies), no alternative to a drug acting on the renin-angiotensin system will be found. In these rare cases, the mothers should be apprised of the potential hazards to their fetuses and serial ultrasound examinations should be performed to assess the intra-amniotic environment.

If oligohydramnios is observed, discontinue Benicar unless it is considered life-saving for the mother. Contraction stress testing (CST), a nonstress test (NST) or biophysical profiling (BPP) may be appropriate, depending upon the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury.

Infants with histories of in utero exposure to an angiotensin II receptor antagonist should be closely observed for hypotension, oliguria and hyperkalemia. If oliguria occurs, attention should be directed toward support of blood pressure and renal perfusion. Exchange transfusion or dialysis may be required as means of reversing hypotension and/or substituting for disordered renal function.
The course method will determine which group to assign the first patient to meet the criteria for inclusion in the study by the researcher. Subsequent patients will be distributed to groups in turn. It is planned to include 40 participants in the study, as losses may occur among the participants. The study will begin on the day that cancer-treated participants receive chemotherapy for the first time. Considering that the participants would be more comfortable and the training would be healthy, the training was planned 30 minutes before the application. The training was planned by the researcher in the chemotherapy case manager's room as face-to-face meetings with each participant separately. Each training will be accompanied by a chemotherapy case manager. Training time is between 20-30 minutes as planned.
Chronic kidney disease (CKD) is characterized by high incidence, prolonged course, significant health damage, and a heavy societal burden. Understanding the history and content of CKD research is crucial to further its recognition and management, in addition to reducing its individual and societal burdens. This study aimed to assess the management history of CKD to provide a foundation for clinical medical staff to systematically understand its evolution. The Web of Science Core Collection database was screened for CKD management studies published between January 1, 1948, and December 31, 2021. From the search results, we performed statistical descriptions of the publication date, volume, and type. Using VOS-viewer 1.6.19, variables from the included articles were obtained for keyword co-occurrence clustering and sequence analyses to determine research themes, segment phases based on publication volumes over varied timeframes, assess the dynamic progression of CKD management, and anticipate future research trends. In total, 26,133 articles met the inclusion criteria. The analysis revealed 3 stages of CKD management research: the slow development stage (1948-1998), which was initiated by epidemiological studies without ideal clustering; the steady growth stage (1999-2010), which was focused on CKD complication management and quality-of-life research; and the rapid development stage (2011-2022), which was dominated by 7 major clusters, mainly regarding the treatment and management of severe conditions and management patterns. The CKD research journey is comprised of 3 stages, the contents of which form an interconnected research model. Future research should focus on the establishment of management models and the application of intelligent management tools. Furthermore, this work can serve as a reference for the further expansion of research in this field and in improving its management.
Sarcopenia, the progressive decline in skeletal muscle mass and function, is observed in various conditions, including cancer and aging. The complex molecular biology of sarcopenia has posed challenges for the development of FDA-approved medications, which have mainly focused on dietary supplementation. Targeting a single gene may not be sufficient to address the broad range of processes involved in muscle loss. This study analyzed the gene expression signatures associated with cancer formation and 5-FU chemotherapy-induced muscle wasting. Our findings suggest that dimenhydrinate, a combination of 8-chlorotheophylline and diphenhydramine, is a potential therapeutic for sarcopenia. In vitro experiments demonstrated that dimenhydrinate promotes muscle progenitor cell proliferation through the phosphorylation of Nrf2 by 8-chlorotheophylline and promotes myotube formation through diphenhydramine-induced autophagy. Furthermore, in various in vivo sarcopenia models, dimenhydrinate induced rapid muscle tissue regeneration. It improved muscle regeneration in animals with Duchenne muscular dystrophy (DMD) and facilitated muscle and fat recovery in animals with chemotherapy-induced sarcopenia. As an FDA-approved drug, dimenhydrinate could be applied for sarcopenia treatment after a relatively short development period, providing hope for individuals suffering from this debilitating condition.
Alzheimer's disease (AD) leads to progressive cognitive decline. Increased amyloid beta (Aβ) burden and Aβ deposits have been shown in the AD retina. Aβ accumulation inside retinal pericytes in AD and pericyte degeneration in the retina mirror prominent features of brain AD pathology. Curcumin, a derivative of turmeric, has a high affinity for amyloid beta. Thus, curcumin would bind to amyloid beta plaques and emit a strong fluorescent signal, suggesting it can be a powerful diagnostic tool for AD. Emerging evidence has shown the connection between the brain and GI tract (gut microbiome), and its potential implications for both metabolic and neurologic diseases including AD. This pilot study is to test how two weeks of curcumin supplementation would cross the blood brain barrier and attach to amyloid beta proteins and to explore the resulting abundance/composition of gut microbiota. The investigators plan to recruit subjects through direct person-to-person solicitation in the Ophthalmology clinics, health fairs, community events, flyers, non-solicited email system, campus announcements, Clinical Research Institute Volunteer Database website, local radio, newspapers, senior newsletters, and TV scripts. The Clinical Research Institute Volunteer database will also be queried and potential subjects contacted as requested in their form. The investigators plan to enroll approximately 100-150 patients to obtain 30-40 qualified subjects at the start of the study. After screening, qualified participants will be randomly assigned to a low curcumin group or high curcumin group. Thus, this pilot study would focus on characterizing the distribution, manifestation, and prevalence of curcumin-loaded retinal Aβ deposits in study subjects with existing Aβ plaque (primary outcome). In addition, this study will assess safety, bioavailability, and fecal microbiome composition (secondary outcome). All outcomes will be assessed at baseline and after 2 weeks of intervention. Data will be analyzed statistically.